Good afternoon :)
Place Order
Add to Watchlist

Marksans Pharma Ltd

MARKSANS Share Price

249.750.16% (-0.40)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹11,335 cr, stock is ranked 499

Stock is 4.04x as volatile as Nifty

MARKSANS Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹11,335 cr, stock is ranked 499

Stock is 4.04x as volatile as Nifty

MARKSANS Performance & Key Metrics

MARKSANS Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
29.785.430.32%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.656.550.84%

MARKSANS Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 3 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

MARKSANS Company Profile

Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.

Investor Presentation

View older View older 

May 19, 2025

PDF
View Older Presentations

MARKSANS Similar Stocks (Peers)

Compare with peers Compare with peers 

MARKSANS Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.18
36.18
1Y Return
8.35%
8.35%
Buy Reco %
87.88
87.88
PE Ratio
22.95
22.95
1Y Return
5.01%
5.01%
Buy Reco %
74.19
74.19
PE Ratio
19.32
19.32
1Y Return
9.60%
9.60%
Buy Reco %
56.67
56.67
PE Ratio
57.15
57.15
1Y Return
11.78%
11.78%
Buy Reco %
72.00
72.00
PE Ratio
48.88
48.88
1Y Return
5.10%
5.10%
Buy Reco %
81.25
81.25
Compare with Peers

MARKSANS Sentiment Analysis

MARKSANS Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

MARKSANS Stock Summary · May 2025

Marksans Pharma is poised for robust growth, particularly in the U.S. market, where it anticipates a year-on-year increase exceeding 25%. Despite achieving record highs in revenue and profit, challenges such as a slower cough and cold season and rising operational costs have impacted EBITDA margins. The company is strategically expanding its product pipeline, with plans to launch around 70 new products by September 2025, while maintaining a strong cash position and a debt-free status. However, rising tariffs and increased working capital days pose risks to profitability and cash flow management. Overall, management remains optimistic about future growth, driven by strategic initiatives and market demand.

MARKSANS Stock Growth Drivers
MARKSANS Stock Growth Drivers
7
  • Strong Financial Performance

    Marksans Pharma has reported significant financial achievements, including a record high in operating revenue of

  • Market Growth and Expansion

    The company has experienced substantial growth in various markets, particularly in the U.S., where revenue

MARKSANS Stock Challenges
MARKSANS Stock Challenges
6
  • Decreased EBITDA Margin

    The company has experienced a decline in its EBITDA margin, which decreased by 183 basis

  • Impact of Tariffs on Pricing

    There are significant concerns regarding the potential impact of U.S. tariffs on the company's operations.

MARKSANS Forecast

MARKSANS Forecasts

Price

Revenue

Earnings

MARKSANS

MARKSANS

Income

Balance Sheet

Cash Flow

MARKSANS Income Statement

MARKSANS Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 17.27%, vs industry avg of 9.02%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.46% to 0.59%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 32.62%, vs industry avg of 15.29%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue774.18921.161,004.691,134.541,382.871,532.691,911.452,227.832,693.222,693.23
Raw Materialssubtract506.68502.58517.91514.88731.33703.92927.751,111.982,094.212,094.20
Power & Fuel Costsubtract12.9711.5513.9914.0016.4218.5924.5036.94
Employee Costsubtract149.70147.75159.07168.42197.32220.30239.37293.64
Selling & Administrative Expensessubtract65.1888.83109.58120.38154.55148.41227.00236.41
Operating & Other expensessubtract-12.1283.6067.38124.28-63.05140.7494.2039.86
Depreciation/Amortizationsubtract30.0926.8422.8026.6636.1544.7851.8574.2783.3983.38
Interest & Other Itemssubtract6.7810.229.668.757.998.459.1311.2011.6611.66
Taxes & Other Itemssubtract6.0616.8627.8436.4266.2262.9571.34109.83123.39123.39
EPS0.220.801.872.955.764.516.186.928.408.40
DPS0.050.050.050.100.250.250.500.600.800.60
Payout ratio0.230.060.030.030.040.060.080.090.100.07

MARKSANS Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

May 19PDF
Feb 11PDF
Nov 12PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
Feb 13PDF
Nov 14PDF
Aug 13PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

May 30PDF
Feb 11PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

MARKSANS Stock Peers

MARKSANS Past Performance & Peer Comparison

MARKSANS Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Marksans Pharma Ltd29.795.430.32%
Sun Pharmaceutical Industries Ltd36.185.890.97%
Cipla Ltd22.954.511.07%
Dr Reddy's Laboratories Ltd19.323.870.61%

MARKSANS Stock Price Comparison

Compare MARKSANS with any stock or ETF
Compare MARKSANS with any stock or ETF
MARKSANS
Loading...

MARKSANS Holdings

MARKSANS Shareholdings

MARKSANS Promoter Holdings Trend

MARKSANS Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

MARKSANS Institutional Holdings Trend

MARKSANS Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

MARKSANS Shareholding Pattern

MARKSANS Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding43.87%3.37%1.18%22.20%29.37%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

MARKSANS Shareholding History

MARKSANS Shareholding History

Dec '23MarJunSepDec '24Mar15.56%15.57%18.60%21.31%21.96%22.20%

Mutual Funds Invested in MARKSANS

Mutual Funds Invested in MARKSANS

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Marksans Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.5653%3.16%0.38%8/47 (+3)
0.4690%3.15%-0.15%15/26 (-1)
0.4473%2.33%0.77%12/48 (+12)

Compare 3-month MF holding change on Screener

MARKSANS Insider Trades & Bulk Stock Deals

MARKSANS Insider Trades & Bulk Stock Deals

Loading...

smallcases containing MARKSANS stock

smallcases containing MARKSANS stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Marksans Pharma Ltd

Loading...
Private Equity Investing Theme

Private Equity Investing Theme

Created by Windmill Capital

MARKSANS's Wtg.
6.67%
6.67%
CAGR
27.32%

MARKSANS Events

MARKSANS Events

MARKSANS Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

MARKSANS has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.31%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.10 every year

Dividends

Corp. Actions

Announcements

Legal Orders

MARKSANS Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

MARKSANS has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.31%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.10 every year

MARKSANS Upcoming Dividends

MARKSANS Upcoming Dividends

No upcoming dividends are available

MARKSANS Past Dividends

MARKSANS Past Dividends

Cash Dividend

Ex DateEx DateSep 17, 2024

Final
Final | Div/Share: ₹0.60

Dividend/Share

0.60

Ex DateEx Date

Sep 17, 2024

Cash Dividend

Ex DateEx DateJun 7, 2023

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Jun 7, 2023

Cash Dividend

Ex DateEx DateAug 19, 2022

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Aug 19, 2022

Cash Dividend

Ex DateEx DateSep 15, 2021

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Sep 15, 2021

Cash Dividend

Ex DateEx DateSep 22, 2020

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Sep 22, 2020

MARKSANS Stock News & Opinions

MARKSANS Stock News & Opinions

Spotlight
Marksans Pharma's UK arm gets marketing nod for Oxybutynin Oral solution from UKMHRA

Oxybutynin is used in the treatment of overactive bladder (OAB) symptoms. OAB is a collection of urinary symptoms, including frequent urination, urgent need to urinate, and inability to control urination. Marksans Pharma is engaged in research, manufacturing & marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies, including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, anti-diabetic, pain management, gastroenterological, and antiallergic. The company is marketing these products globally. The company reported a 15.7% increase in consolidated net profit to Rs 90.55 crore on a 26.5% rise in revenue from operations to Rs 708.46 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.36% to currently trade at Rs 251.30 on the BSE. Powered by Capital Market - Live

5 hours agoCapital Market - Live
Spotlight
Marksans Pharma gets regulatory nod for marketing type-2 diabetes medication in UK

Metformin Hydrochloride is a widely prescribed medication used for the management of type-2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. This regulatory approval would enable Marksans Pharma to market and distribute the said oral solution in the UK. Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. The scrip rose 0.38% to currently trade at Rs 261.35 on the BSE. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Relonchem receives marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution in UK

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Board of Marksans Pharma recommends final dividend

Marksans Pharma announced that the Board of Directors of the Company at its meeting held on 19 May 2025, inter alia, have recommended the final dividend of Rs 0.8 per equity Share (i.e. 80%) , subject to the approval of the shareholders.Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Earnings
Marksans Pharma consolidated net profit rises 15.66% in the March 2025 quarter

Net profit of Marksans Pharma rose 15.66% to Rs 90.55 crore in the quarter ended March 2025 as against Rs 78.29 crore during the previous quarter ended March 2024. Sales rose 26.51% to Rs 708.46 crore in the quarter ended March 2025 as against Rs 560.01 crore during the previous quarter ended March 2024. For the full year,net profit rose 21.32% to Rs 380.58 crore in the year ended March 2025 as against Rs 313.70 crore during the previous year ended March 2024. Sales rose 20.46% to Rs 2622.85 crore in the year ended March 2025 as against Rs 2177.41 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales708.46560.01 27 2622.852177.41 20 OPM %17.7519.58 -20.1521.06 - PBDT138.84121.33 14 587.35497.80 18 PBT116.09100.28 16 503.97423.53 19 NP90.5578.29 16 380.58313.70 21 Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Relonchem receives marketing authorization for Sennosides 7.5 mg tablets

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Sennosides 7.5 mg Tablets from UK Medicines & Healthcare Products Regulatory Agency.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Relonchem receives marketing authorization for Gabapentin 50 mg/ml oral solution

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Marksans Pharma to conduct board meeting

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York

Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at 7, Michael Avenue, Farmingdale, New York, USA ('the Subsidiary') from 16 April 2025 to 24 April 2025. On conclusion of the inspection, the Subsidiary has received One (1) inspectional observation in Form 483. There is no data integrity observation. The Subsidiary will work closely with the USFDA and is committed to address the observation comprehensively within the stipulated time. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Marksans Pharma gains as USFDA concludes inspection at New York unit

The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturing facility in Farmingdale, New York. At the end of the inspection, the subsidiary received one observation, documented in the USFDA's Form 483. Notably, the inspection did not raise any concerns regarding data integrity. Marksans Pharma confirmed that it will work closely with the USFDA to address the observation within the prescribed timeline. Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live

1 month agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Marksans Pharma Ltd (MARKSANS) today?

    The share price of MARKSANS as on 19th June 2025 is ₹249.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Marksans Pharma Ltd (MARKSANS) share?

    The past returns of Marksans Pharma Ltd (MARKSANS) share are
    • Past 1 week: -1.18%
    • Past 1 month: 3.38%
    • Past 3 months: 23.43%
    • Past 6 months: -21.84%
    • Past 1 year: 56.44%
    • Past 3 years: 492.77%
    • Past 5 years: 629.30%

  3. What are the peers or stocks similar to Marksans Pharma Ltd (MARKSANS)?
  4. What is the dividend yield % of Marksans Pharma Ltd (MARKSANS) share?

    The current dividend yield of Marksans Pharma Ltd (MARKSANS) is 0.32.

  5. What is the market cap of Marksans Pharma Ltd (MARKSANS) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Marksans Pharma Ltd (MARKSANS) is ₹11335.89 Cr as of 19th June 2025.

  6. What is the 52 week high and low of Marksans Pharma Ltd (MARKSANS) share?

    The 52-week high of Marksans Pharma Ltd (MARKSANS) is ₹358.70 and the 52-week low is ₹157.06.

  7. What is the PE and PB ratio of Marksans Pharma Ltd (MARKSANS) stock?

    The P/E (price-to-earnings) ratio of Marksans Pharma Ltd (MARKSANS) is 29.79. The P/B (price-to-book) ratio is 5.43.

  8. Which sector does Marksans Pharma Ltd (MARKSANS) belong to?

    Marksans Pharma Ltd (MARKSANS) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Marksans Pharma Ltd (MARKSANS) shares?

    You can directly buy Marksans Pharma Ltd (MARKSANS) shares on Tickertape. Simply sign up, connect your demat account and place your order.